All In Biotech

Drug Trial Radar · NCT05270525

Effect of Ensifentrine (MK-5884/RPL554) on Sputum Markers of Inflammation in Chronic Obstructive Pulmonary Disease (COPD) (MK-5884-023/RPL554-CO-207)

A Randomized, Double-Blind, Placebo-Controlled, Two-period Cross-over Study of the Effect of Ensifentrine on Sputum Markers of Inflammation in Subjects With COPD

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

70

Actual

Start

May 27, 2022

Primary completion

Mar 1, 2027

Study completion Mar 1, 2027

Sponsor

Sponsor type
Industry
Collaborators
University of Alabama at Birmingham
First posted
Mar 8, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for new ways to treat chronic obstructive pulmonary disease (COPD). COPD is a long-lasting swelling of the airways that makes it hard to breathe. Researchers want to learn if a trial medicine called ensifentrine can help treat sputum caused by COPD. In this trial, researchers will compare a trial medicine called ensifentrine to a placebo. A placebo looks like the trial medicine but has no medicine in it. Using a placebo helps researchers better understand the effects of a trial medicine. The goal of this trial is to learn about the effect of ensifentrine on a substance found in mucus (sputum) from the lungs that may be a sign of inflammation in participants with COPD.

Conditions

  • Pulmonary Disease, Chronic Obstructive, COPD

Interventions

  • EnsifentrineDrug

    Ensifentrine administered twice daily by oral inhalation via a standard jet nebulizer.

  • PlaceboDrug

    Placebo matching ensifentrine administered twice daily by oral inhalation via a standard jet nebulizer.

  • LABA/LAMADrug

    Background treatment of LAMA/LABA administered per product approved label delivered by oral inhalation.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Absolute Change From Baseline in Sputum Neutrophil Cell NumbersTime frame: Baseline and 8 Weeks

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • University of Michigan

    Ann Arbor, Michigan

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.